Back to Search

Nafamostat Mesylate for Bleeding Patients on Dialysis

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Recruiting N/A Interventional Study
Dialysis; Complications Bleeding
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 99
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
100 (estimated)
Sponsor
Wonju Severance Christian Hospital · Other
Who this trial is looking for

This trial is looking for patients who are at high risk for bleeding and are undergoing hemodialysis. Participants will receive nafamostat or a standard treatment to see how safe it is.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have a platelet count below 10,000.
  • I have a PTT above 60 seconds.
  • I have an INR above 2.0.
  • I have experienced certain types of bleeding.
  • I had a brain hemorrhage within the last 6 months.
  • I am currently receiving anticoagulant therapy.
  • I am using a dual antiplatelet agent.
  • I have had major surgery within the last month.

You may not be able to join if

  • I have cancer.
  • I have liver cirrhosis.
  • I am pregnant.
  • I have a drug allergy.
  • I am currently bleeding from a major organ.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Comparison nafamostat and low molecular weight heparin among dialysis patients

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month…
Contacts

No contact information available.

NCT ID: NCT05874674 Source: ClinicalTrials.gov